BRAF and Hypertension: Cardiovascular adverse events (CVAEs) associated with BRAF and MEK inhibitors have been reported in several studies, particularly regarding a reduction in left ventricular ejection fraction (LVEF), arterial hypertension, and prolongation of QTc interval.